Under construction – not a live service

Skip to content

Frontlight Research

Institution

Tel Aviv Sourasky Medical Center

Tel Aviv, IsraelWebsite

Also known as: Ichilov Hospital

239running trials
90closed trials
23,986publications (OpenAlex)

Running trials

Recruiting
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT07746687· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
NCT07665450· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
NCT07227896· AbbVie· Source
Recruiting
Tele-Pulmonary Rehabilitation For Patients With Chronic Lung Diseases
NCT07666841· Tel-Aviv Sourasky Medical Center· Source
Recruiting
Post Exacerbation Asthma Clinic Telecare Intervention to Reduce Recurrent Exacerbations
NCT07629830· Tel-Aviv Sourasky Medical Center· Source
Recruiting
COPD Flare-Up Clinic After Severe Exacerbations
NCT07629869· Tel-Aviv Sourasky Medical Center· Source
Recruiting
Tele-Pulmonary Rehabilitation For COPD Patients Living in Peripheral Areas
NCT07666854· Tel-Aviv Sourasky Medical Center· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002· Phase 2/3· AbbVie· Source
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
NCT07913152· Tel-Aviv Sourasky Medical Center· Source
Not yet recruiting
SCI-110 in the Treatment of Tourette Syndrome
NCT05126888· Phase 2· Neurothera Labs Inc.· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
BIO|STREAM.CSP Study
NCT07393009· Biotronik SE & Co. KG· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
NCT07249905· Phase 1/2· ModeX Therapeutics, An OPKO Health Company· Source
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341· Phase 4· Eli Lilly and Company· Source
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
NCT07409246· Phase 1· AbbVie· Source
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003· Phase 3· Prilenia· Source
Recruiting
Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .
NCT07191249· Phase 2· Tel-Aviv Sourasky Medical Center· Source
Recruiting
Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study
NCT07380737· Tel-Aviv Sourasky Medical Center· Source
Recruiting
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947· Phase 2· Tyra Biosciences, Inc· Source
Recruiting
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
NCT07485114· Daniel Keizman· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
NCT07196644· Phase 2· AbbVie· Source
Recruiting
MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC
NCT07327021· Phase 2· Tel-Aviv Sourasky Medical Center· Source
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065· Phase 3· AbbVie· Source
Recruiting
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
NCT07293923· Magenta Medical Ltd.· Source
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285· Bristol-Myers Squibb· Source
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Recruiting
Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome
NCT06821568· Hebrew SeniorLife· Source
Not yet recruiting
Plant vs Animal-based Protein Sources as an Anabolic and Metabolic-protective Options for SO in Older Adults
NCT07030738· Tel-Aviv Sourasky Medical Center· Source
Recruiting
Impact of Advanced Crohn's Disease Therapies on Sleep Quality
NCT07649408· Shmuel Kivity, MD· Source
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
NCT07024784· Phase 2· AbbVie· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960· Phase 1/2· AbbVie· Source
Active, not recruiting
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· Phase 3· AbbVie· Source
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Early Beta Blocker Administration in STEMI Patients With SCAI B Status
NCT06967194· Tel-Aviv Sourasky Medical Center· Source
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· Phase 3· Takeda· Source
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463· Phase 2· AbbVie· Source
Recruiting
Steps Against the Burden of Parkinson's Disease - TelAviv/Bologna
NCT07105787· University of Kiel· Source
Recruiting
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
NCT06830759· AbbVie· Source
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· Phase 3· Daiichi Sankyo· Source

Showing 50 of 239.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
Description of Patients With Type 1 Diabetes Treated With Teplizumab
NCT06892002· Sanofi· Source
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· Phase 2· AbbVie· Source
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277· Phase 3· Bayer· Source
Terminated
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
NCT06478862· Phase 2· Lipomedix Pharmaceuticals Inc.· Source
Completed
Study of Intra-articular Allocetra in Knee Osteoarthritis
NCT06233474· Phase 1/2· Enlivex Therapeutics Ltd.· Source
Completed
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· Phase 3· GB002, Inc.· Source
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318· Janssen-Cilag Ltd.· Source
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Terminated
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
NCT06068868· Phase 1· AbbVie· Source
Completed
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
NCT05978622· AbbVie· Source
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· Phase 3· AbbVie· Source
Completed
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05858164· Phase 1· Bayer· Source
Completed
An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
NCT05827887· AbbVie· Source
Completed
A Longitudinal Evaluation of Oculometric Measures and Clinical Assessment Over Time in PD Patients
NCT05795023· NeuraLight· Source
Completed
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
NCT05483907· Phase 2· Bridge Biotherapeutics, Inc.· Source
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source
Completed
A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)
NCT05551741· Phase 1· Immunobrain Checkpoint· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Bayer· Source
Completed
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216· Phase 3· Abivax S.A.· Source
Terminated
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05325866· Phase 1/2· Amgen· Source
Completed
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
NCT05153239· Phase 3· PharmaMar· Source
Completed
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT04919512· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
NCT05357950· Phase 2· NeuroSense Therapeutics Ltd.· Source
Completed
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
NCT05348785· Phase 2· Biogen· Source
Completed
A Gene Therapy Study in Patients With Gaucher Disease Type 1
NCT05324943· Phase 1· Spur Therapeutics· Source
Completed
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source
Completed
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source
Completed
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
NCT05081557· AbbVie· Source
Terminated
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
NCT05028569· Phase 3· AbbVie· Source
Completed
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
NCT04779307· Phase 3· Takeda· Source
Completed
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
NCT05047263· Phase 3· Bayer· Source
Completed
A Study of Surgical Interventions in Fistulizing Conditions
NCT04940611· Takeda· Source
Terminated
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551053· Phase 3· Incyte Corporation· Source
Terminated
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551066· Phase 3· Incyte Corporation· Source
Completed
Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice
NCT04517669· Pfizer· Source
Completed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344· Phase 3· Hoffmann-La Roche· Source
Completed
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
NCT04813653· Phase 1· Tel-Aviv Sourasky Medical Center· Source
Completed
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source
Completed
Detection of Cancer in Breath Samples by Trained Detection Dogs
NCT06255041· SpotitEarly· Source
Completed
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
NCT04696055· Phase 2· Bayer· Source
Terminated
Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion
NCT04529954· Phase 1/2· Cerebral Therapeutics LLC· Source
Completed
Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain
NCT04630990· AbbVie· Source
Completed
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
NCT04471844· NovoCure Ltd.· Source
Completed
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT04497597· AbbVie· Source
Completed
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
NCT04472598· Phase 3· AbbVie· Source
Completed
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
NCT04543617· Phase 3· Hoffmann-La Roche· Source
Completed
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
NCT04435626· Phase 3· Bayer· Source
Terminated
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
NCT04153175· Phase 2· Cerebral Therapeutics LLC· Source
Recruiting
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
NCT04414475· Phase 2· Karyopharm Therapeutics Inc· Source

Showing 50 of 90.

Registry name variants (109)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Tel-Aviv Sourasky Medical Center
Tel Aviv, 64239
192 trials
The Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
12 trials
Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center
Tel Aviv
5 trials
Tel Aviv Sourasky Medical Ctr
Tel Aviv, 6423906
5 trials
Sourasky / Ichilov Hospital
Tel Aviv, 6423906
3 trials
- NCT07413939RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- NCT04589845Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT03456063A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Tel Aviv Sourasky Medical Center, 6 Weizmann St.
Tel Aviv, 64239
3 trials
- NCT04127578Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
- NCT03683186A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
- NCT03626688A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Tel Aviv, 6423906
3 trials
- NCT07380737Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study
  Contact: Sourasky Medical Cente
- NCT06839144Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
  Contact: Nadav Michaan, Prof.
- NCT03364153Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
Tel Aviv Sourasky Medical Centre
Tel Aviv, 64239
3 trials
- NCT03590171International Study for Treatment of High Risk Childhood Relapsed ALL 2010
  Contact: Ronit Elhasid, MD
- NCT02992964Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
- NCT03127631A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Ichilov Hospital
Tel Aviv
2 trials
- NCT07759193Energy Expenditure Assessment in Head and Neck Cancer Patients Treated With Free Flap Surgery
  Contact: Efrat Haruoch Harouch
- NCT02699736EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
Sourasky Tel Aviv Medical Center
Tel Aviv, 6423906
2 trials
- NCT06973187A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  Contact: Study Director
- NCT05100862A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Tel Aviv Sourasky Medical Center
Ashkelon, Southern District 78278
2 trials
- NCT06097260Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- NCT05483907To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
Tel- Aviv Sourasky Medical Center - Nephrology
Tel Aviv, 6423906
2 trials
- NCT05858164A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
- NCT04597125RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Tel Aviv Sourasky Medical Center - TASMC
Tel Aviv, 64239
2 trials
- NCT05735704Early Detection and Screening of Hematological Malignancies - SANGUINE
  Contact: Miri Neaman, MD
- NCT03866603Rostock International Parkinson's Disease Study (ROPAD)
The Tel-Aviv Sourasky Medical Centre
Tel Aviv
2 trials
- NCT07449936COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
- NCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
3760038 - Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Ichilov - Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906
1 trial
- NCT06233474Study of Intra-articular Allocetra in Knee Osteoarthritis
Movement Disorders Unit, Sourasky Tel Aviv Medical Center
Tel Aviv, 6423906
1 trial
- NCT05795023A Longitudinal Evaluation of Oculometric Measures and Clinical Assessment Over Time in PD Patients
Neurological Institute, Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
1 trial
- NCT05126888SCI-110 in the Treatment of Tourette Syndrome
  Contact: Tanya Gurevich, PhD. MD
Pharmacy - clinical unit, Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906
1 trial
- NCT02684006A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Sourasky / Ichilov Hospital; Dept. of Oncology
Tel Aviv, 6423906
1 trial
- NCT03178552A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Tel Aviv Sourasky Medical Center
Tel Aviv Yaffo, Central District 64239
1 trial
- NCT06398743First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
Tel-Aviv Sourasky Medical Center
Holon, 582201
1 trial
- NCT04174157Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
  Contact: Aviva Fattal, MD
Tel Aviv Sourasky Medical Center /ID# 130276
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Tel Aviv Sourasky Medical Center /ID# 154175
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Tel Aviv Sourasky Medical Center /ID# 157792
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Tel Aviv Sourasky Medical Center /ID# 169437
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03539744A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
Tel Aviv Sourasky Medical Center /ID# 169845
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03104400A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Tel Aviv Sourasky Medical Center /ID# 201608
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03568318A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Tel Aviv Sourasky Medical Center /ID# 206450
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03345823A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
Tel Aviv Sourasky Medical Center /ID# 206962
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03659669A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
Tel Aviv Sourasky Medical Center /ID# 213354
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03987958A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)
Tel Aviv Sourasky Medical Center /ID# 216956
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04169373A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
Tel Aviv Sourasky Medical Center /ID# 219134
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Tel Aviv Sourasky Medical Center /ID# 219135
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Tel Aviv Sourasky Medical Center /ID# 221896
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Tel Aviv Sourasky Medical Center /ID# 222117
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04497597A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Tel Aviv Sourasky Medical Center /ID# 222199
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Tel Aviv Sourasky Medical Center /ID# 223548
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04454658Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Tel Aviv Sourasky Medical Center /ID# 223551
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04524611Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Tel Aviv Sourasky Medical Center /ID# 224765
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04630990Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain
Tel Aviv Sourasky Medical Center /ID# 225891
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Tel Aviv Sourasky Medical Center /ID# 226564
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04780516Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care
Tel Aviv Sourasky Medical Center /ID# 228529
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Tel Aviv Sourasky Medical Center /ID# 230311
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03222609A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
Tel Aviv Sourasky Medical Center /ID# 232598
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05028569Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Tel Aviv Sourasky Medical Center /ID# 239698
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04102020A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
Tel Aviv Sourasky Medical Center /ID# 240311
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT03891446Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Tel Aviv Sourasky Medical Center /ID# 243012
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05283720A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Tel Aviv Sourasky Medical Center /ID# 243218
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04895436Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Tel Aviv Sourasky Medical Center /ID# 244907
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05081557A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
Tel Aviv Sourasky Medical Center /ID# 245271
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05029882Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Tel Aviv Sourasky Medical Center /ID# 245495
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06158841Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Tel Aviv Sourasky Medical Center /ID# 247466
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05711394A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Tel Aviv Sourasky Medical Center /ID# 250483
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05308654A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Tel Aviv Sourasky Medical Center /ID# 250562
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05494606An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
Tel Aviv Sourasky Medical Center /ID# 251133
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05707949Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
Tel Aviv Sourasky Medical Center /ID# 251573
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05650632A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Tel Aviv Sourasky Medical Center /ID# 252858
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05843643Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Tel Aviv Sourasky Medical Center /ID# 252914
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06068868Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Tel Aviv Sourasky Medical Center /ID# 254404
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Tel Aviv Sourasky Medical Center /ID# 254824
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06107426Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Tel Aviv Sourasky Medical Center /ID# 257057
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05841537An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Tel Aviv Sourasky Medical Center /ID# 257090
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Tel Aviv Sourasky Medical Center /ID# 257771
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06012240A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Tel Aviv Sourasky Medical Center /ID# 258528
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06257875A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Tel Aviv Sourasky Medical Center /ID# 258931
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06084481Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Tel Aviv Sourasky Medical Center /ID# 259608
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05753501Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Tel Aviv Sourasky Medical Center /ID# 259850
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06118411A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
Tel Aviv Sourasky Medical Center /ID# 259933
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06191744Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Tel Aviv Sourasky Medical Center /ID# 260519
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT04928846A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Tel Aviv Sourasky Medical Center /ID# 261525
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06223516Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
Tel Aviv Sourasky Medical Center /ID# 261659
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06667687Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Tel Aviv Sourasky Medical Center /ID# 263089
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05827887An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
Tel Aviv Sourasky Medical Center /ID# 265469
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05978622Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
Tel Aviv Sourasky Medical Center /ID# 266246
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT07007065Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Tel Aviv Sourasky Medical Center /ID# 266581
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Tel Aviv Sourasky Medical Center /ID# 267307
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06548542Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Tel Aviv Sourasky Medical Center /ID# 267578
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06614192A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Tel Aviv Sourasky Medical Center /ID# 267755
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06628310A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Tel Aviv Sourasky Medical Center /ID# 268010
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06820463A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Tel Aviv Sourasky Medical Center /ID# 269455
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Tel Aviv Sourasky Medical Center /ID# 270106
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06632951Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Tel Aviv Sourasky Medical Center /ID# 271252
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06953960A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Tel Aviv Sourasky Medical Center /ID# 271615
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06830759Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
  Contact: Rebekah Taylor
Tel Aviv Sourasky Medical Center /ID# 273311
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06764693An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
  Contact: Shari Chapman
Tel Aviv Sourasky Medical Center /ID# 273351
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT06880744A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Tel Aviv Sourasky Medical Center /ID# 274344
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT07196644A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Tel Aviv Sourasky Medical Center /ID# 275852
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Tel Aviv Sourasky Medical Center /ID# 276212
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT07227896Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
  Contact: Lars Bergmann
Tel Aviv Sourasky Medical Center /ID# 276591
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Tel Aviv Sourasky Medical Center /ID# 278717
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Tel Aviv Sourasky Medical Center /ID# 279066
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT07409246A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Tel Aviv Sourasky Medical Center - Neurosurgery
Tel Aviv, 64239
1 trial
- NCT07355218A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
  Contact: Communication Center
Tel Aviv Sourasky Medical Center - Oncology
Tel Aviv, 6423906
1 trial
- NCT03778931Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Tel Aviv Sourasky Medical Center - Oncology Department
Tel Aviv, 6423906
1 trial
- NCT06452277A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
Tel Aviv, 64239
1 trial
- NCT06087458Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Tel Aviv Sourasky Medical Center (Site 0900)
Tel Aviv, 6423906
1 trial
- NCT03040999Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Tel Aviv Sourasky Medical Center (Site 1714)
Tel Aviv, 64239
1 trial
- NCT04945460A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Tel Aviv Sourasky Medical Center (Site 4606)
Tel Aviv, 6423906
1 trial
- NCT05270668Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Tel Aviv Sourasky Medical Center,Substudy-01
Tel Aviv, 64239
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Tel Aviv Sourasky Medical Center,Substudy-02
Tel Aviv, 64239
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Tel-Aviv Sourasky Medical Center,Substudy-03
Tel Aviv, 64239
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Tel Aviv Sourasky Medical Center (TASMC) - Ichilov
Tel Aviv
1 trial
- NCT07191249Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .
  Contact: Irit Avivi, Prof
Tel-Aviv Sourasky Medical Center, Tel Aviv
Tel Aviv
1 trial
- NCT07629830Post Exacerbation Asthma Clinic Telecare Intervention to Reduce Recurrent Exacerbations
  Contact: Amir Bar-Shai, MD
Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906
Tel Aviv
1 trial
- NCT07629869COPD Flare-Up Clinic After Severe Exacerbations
  Contact: Ophir Freund, Medical Doctor (Pulmonologist)
Tel Aviv Sourasky Medical Ctr /ID# 144709
Tel Aviv, Tel Aviv 6423906
1 trial
- NCT02629159A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
The Tel Aviv Sourasky Medical Center, Department of Hematology and Bone Marrow Transplantation, Leukemia Service
Tel Aviv, 6423906
1 trial
- NCT06499285A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Contact: Yakir Moshe (principal investigator)
The Tel Aviv Sourasky Medical Center, Department of Internal Medicine
Tel Aviv
1 trial
- NCT03165734A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
The Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Tel Aviv, 6423
1 trial
- NCT02975934A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 04nd58p63 (CC0-1.0)Updated 12 Nov 2026

Report an error

Under construction, not live – Tel Aviv Sourasky Medical Center: trials and research groups – Frontlight Research